2. Protein Tyrosine Kinase/RTK
    Autophagy
    Apoptosis
  3. Bcr-Abl
    Src
    Autophagy
    Apoptosis
  4. Dasatinib

Dasatinib  (Synonyms: BMS-354825)

Cat. No.: HY-10181 Purity: 99.83%
COA Handling Instructions

Dasatinib (BMS-354825) est un double Bcr-Abl et Src famille tyrosine kinase puissant et oralement actif avec des IC50s de 0,6 nM, 0,8 nM, respectivement. Dasatinib inhibe également Abl, Src, Fyn, c-Kit et c-KitD816V avec des IC50 de 2,8 nM, 79 nM et 37 nM, respectivement. Dasatinib induit également l'apoptose et l'autophagie. Dasatinib présente une activité puissante antitumorale et a le potentiel de traiter la leucémie myéloïde chronique (LMC).

Dasatinib (BMS-354825) ist ein hochwirksamer, ATP-kompetitiver, oral aktiver dualer Src/Bcr-Abl-Inhibitor mit starker Antitumor-Aktivität. Die Ki-Werte von 16 pM und 30 pM für Src bzw. Bcr-Abl.

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

For research use only. We do not sell to patients.

Dasatinib Chemical Structure

Dasatinib Chemical Structure

CAS No. : 302962-49-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 73 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 73 In-stock
Estimated Time of Arrival: December 31
Solid
100 mg USD 66 In-stock
Estimated Time of Arrival: December 31
200 mg USD 78 In-stock
Estimated Time of Arrival: December 31
500 mg USD 118 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 73 publication(s) in Google Scholar

Other Forms of Dasatinib:

Top Publications Citing Use of Products

67 Publications Citing Use of MCE Dasatinib

WB
IF

    Dasatinib purchased from MCE. Usage Cited in: Nat Cell Biol. 2023 Feb 27.  [Abstract]

    Dasatinib (50 nM; 24 or 48 h) significantly decreases MED8A and D458 cell migration.

    Dasatinib purchased from MCE. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109.  [Abstract]

    YSE450-R and EC109-R cells are treated with 200 nM BIBW 2992 alone or in combination with 100 nM Dasatinib for 48 h.

    Dasatinib purchased from MCE. Usage Cited in: Biol Pharm Bull. 2017;40(10):1747-1753.  [Abstract]

    Synergistic Decrease Bcl-2 Expression by the Combination of SAHA with Dasatinib in MCF-7 Cells.

    Dasatinib purchased from MCE. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775.  [Abstract]

    Changes in Bcl-2 protein expression in MCF-7 cells after treatment with NSC 105014, Dasatinib or ZD1839 alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.

    Dasatinib purchased from MCE. Usage Cited in: Kawasaki Medical Journal. 43(2)：63-78，2017.

    Western blot analysis of effects of Dasatinib (10 or 100nM) on c-Src, p-SrcY416, FAK and p-FAKY861 expression levels in KTC-1 cells and band intensities for p-SrcY416.

    Dasatinib purchased from MCE. Usage Cited in: Leukemia. 2012 Oct;26(10):2233-44.  [Abstract]

    Drug combination effect on phosphorylation of AKT. Expression of phospho-AKT and total AKT in MOLM13 cells treated for 15 minutes with DMSO vehicle, PKC412 (2.5 nM), Dasatinib (165 nM), or a combination of both. Protein lysates are prepared from MOLM13 cells, and are analyzed via immunoblotting with antibodies to phospho-AKT and total AKT.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib also induces apoptosis and autophagy.

    IC50 & Target[1]

    Bcr-Abl

    1.0 nM (IC50)

    Src

    0.5 nM (IC50)

    lck

    0.4 nM (IC50)

    yes

    0.5 nM (IC50)

    c-kit

    5.0 nM (IC50)

    PDGFRβ

    28 nM (IC50)

    p38

    100 nM (IC50)

    Her1

    180 nM (IC50)

    Her2

    710 nM (IC50)

    FGFR-1

    880 nM (IC50)

    MEK

    1700 nM (IC50)

    In Vitro

    Dasatinib demonstrates significant activity against Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK with IC50s of <1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively[1].
    Dasatinib shows antiproliferative activities aversus K562 chronic myelogenous leukemia (CML), PC3 human prostate tumor, MDA-MB-231 human breast tumor, and WiDr human colon tumor cell lines with IC50s of <1.0 nM, 9.4 nM, 12 nM, and 52 nM, respectively[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    In Vivo

    Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels[1].
    Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. Dasatinib (10 mg/kg) demonstrates favorable half-lives (t1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (Fpo) in this study is 27%[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice bearing K562 xenografts
    Dosage: 5 mg/kg and 50 mg/kg
    Administration: Oral administration on a 5 day on and 2 day off schedule.
    Result: Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed.
    Animal Model: Sprague-Dawley Rats
    Dosage: 10 mg/kg (Pharmacokinetic Analysis)
    Administration: Oral and i.v.
    Result: Cmax of 13.2 and 0.5 μM for i.v. and oral, respectively.
    Clinical Trial
    Molecular Weight

    488.01

    Appearance

    Solid

    Formula

    C22H26ClN7O2S
    CAS No.
    SMILES

    O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 250 mg/mL (512.28 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0491 mL 10.2457 mL 20.4914 mL
    5 mM 0.4098 mL 2.0491 mL 4.0983 mL
    10 mM 0.2049 mL 1.0246 mL 2.0491 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  0.5% MC  0.5% Tween-80

      Solubility: 6.67 mg/mL (13.67 mM); Suspended solution; Need ultrasonic

    • 2.

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% saline

      Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

    • 3.

      Add each solvent one by one:  5% DMSO    95% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

    • 4.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

    • 5.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

    • 6.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation

    Purity: 99.85%

    COA (247 KB) LCMS (135 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    Dasatinib302962-49-8BMS-354825BMS354825BMS 354825Bcr-AblSrcAutophagyApoptosisorallyactiveantitumorantiproliferativeK562CMLPC3prostateMDA-MB-231breastWiDrcolonInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email address *

    Phone number *

    		 

    Organization name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dasatinib
    Cat. No.:
    HY-10181
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email address *

    Phone number

    		 

    Department *

    Organization name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.